

FORM PTO-1390 MODIFIED	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	IAPS Rec'd PCT/PTO 03 JAN 2006 ATTORNEY'S DOCKET NUMBER 4465-6
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) <div style="text-align: right;">10/527,662 <i>#5</i></div>
INTERNATIONAL APPLICATION NO. PCT/EP2003/050402	INTERNATIONAL FILING DATE 11 September 2003	PRIORITY DATE CLAIMED 12 September 2002
TITLE OF INVENTION A METHOD FOR THE IDENTIFICATION OF DRUG TARGETS		
APPLICANT(S) FOR DO/EO/US VANDEKERCKHOVE et al.		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> 1. <input type="checkbox"/> This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. 2. <input checked="" type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input type="checkbox"/> The U.S. has been elected (Article 31). 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (pages specification, claims & abstract (claims), sheets drawings). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (pages specification, claims & abstract (claims), sheets drawings, page Certificate of Translation). b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <ol style="list-style-type: none"> a. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). b. <input type="checkbox"/> Declaration was submitted to the International Bureau during International Phase (see copies of Declaration (page Form PCT/RO/101 and Form PCT/IB/371 and first page of printed publication acknowledging receipt thereof attached). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <p>Items 11 To 20 below concern document(s) or information included:</p> <ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included. 13. <ol style="list-style-type: none"> a. <input type="checkbox"/> A FIRST preliminary amendment. b. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> An Application Data Sheet under 37 C.F.R. § 1.76. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information. Amendment; Notification to Comply dated 11/2/2005; paper & computer readable copies of Sequence Listing 		

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/527,662		INTERNATIONAL APPLICATION NO. PCT/EP2003/050402		ATTORNEY'S DOCKET NUMBER 4465-6	
<input type="checkbox"/> The following fees are submitted:					
BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5):					
21. <input type="checkbox"/>	Basic national fee			\$300.00 (1631)/\$150.00 (2631)	\$
22. <input type="checkbox"/>	Examination Fee.....			\$0 (1643/2643)	\$
				\$200.00 (1633)/\$100.00 (2633)	
23. <input type="checkbox"/>	Search Fee			\$0 (1640/2640)	
				\$100 (1641)/\$50 (2641)	
				\$400 (1642)/\$200 (2642)	
				\$500.00 (1632)/\$250.00 (2632)	
TOTAL OF ABOVE CALCULATIONS					\$ 0.00
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)		RATE	
0 -100	0	/50 =	0.00	\$0.00 (1681)	
				\$0.00 (2681)	
Surcharge of \$130.00 (1617)/\$65.00 (2617) for furnishing the oath or declaration later than <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).					
CLAIMS		NUMBER FILED	# EXTRA	RATE	
Total Claims		minus 20 =	0 X	\$50.00 (1615)/	\$25.00 (2615)
Independent Claims		minus 3 =	0 X	\$200.00 (1614)	\$100.00 (2614)
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)				\$360.00 (1616)/\$180.00 (2616)	
				\$ 0.00	
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s): One Month Extension \$120.00 (1251)/\$60.00 (2251); Two Month Extensions \$450.00 (1252)/\$225.00 (2252); Three Month Extensions \$1020.00 (1253)/\$510.00 (2253); Four Month Extensions \$1590.00 (1254)/\$795.00 (2254)					
				\$ 0.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.					
Processing fee of \$130.00 (1618), for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(f)).					
				+ 0.00	
TOTAL NATIONAL FEE =					\$ 0.00
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). \$40.00 (8021) per property					
				+ 0.00	
Fee for Petition to Revive Unintentionally Abandoned Application; \$1500.00 (1453) / \$750.00 (2453)					\$ 0.00
TOTAL FEES ENCLOSED =					\$ 0.00
					Amount to be refunded:
					\$
					Amount to be Charged:
					\$

U.S. Application No.10/527,662; Atty Docket No.4465-6

- a. ☐ A check in the amount of \$0.00 to cover the above fees is enclosed.
b. ☐ Please charge my Deposit Account No. 14-1140 in the amount of \$_____ to cover the above fees.
A duplicate copy of this form is enclosed.
c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1140. A duplicate copy of this form is enclosed.
d. ☐ **CREDIT CARD PAYMENT FORM ATTACHED.**
e. ☒ The entire content of International Application No. PCT/EP2003/050402 and any U.S. and foreign application(s) corresponding thereto, and EP 02078801.4, referred to in this application is/are hereby incorporated by reference in this application.

NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. 1.137(a) or (b) must be filed and granted to restore the application to pending status.

CORRESPONDENCE ADDRESS

Direct all correspondence to:

☒ **Customer Number:****23117***Type Customer Number here*

Telephone: (703) 816-4000

BJS:pp


B. J. Sadoff

NAME

36,663

REGISTRATION NUMBER

January 3, 2006

Date



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/527,662	Joel Vandekerckhove	4465-6

INTERNATIONAL APPLICATION NO.

PCT/EP03/50402

I.A. FILING DATE	PRIORITY DATE
09/11/2003	09/12/2002

23117

NIXON & VANDERHYE, PC
901 NORTH GLEBE ROAD, 11TH FLOOR
ARLINGTON, VA 22203

DOCKETED

CLT/MATTER # 4465-6MAIL DATE NOV. 2, 2005DUE DATE JAN 2, 2006FINAL DEADLINE JUN 2, 2006DOCKETED BY HK

CONFIRMATION NO. 7309

FORMALITIES LETTER



OC000000017351267

Date Mailed: 11/02/2005

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

TAMALA D HOLLAND

Telephone: (703) 308-9140 EXT 209

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/527,662	PCT/EP03/50402	4465-6

FORM PCT/DO/EO/922 (371 Formalities Notice)

STIC Biotechnology Systems Branch

RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:

Source:

Date Processed by STIC:

10/527,662
PCT
3-24-05

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.2.2 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - cPAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05):
U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/24/05

Best Available Copy

FASTA Sequence Listing Error Summary

ERROR DETECTED

SUGGESTED CORRECTION

SERIAL NUMBER: 10/527,662

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS WHICH WERE INSERTED BY PTO SOFTWARE

1. Wrapped Nucleics
Wrapped Aminos The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."

2. Invalid Line Length The rules require that a line not exceed 72 characters in length. This includes white spaces.

3. Misaligned Amino Numbering The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.

4. Non-ASCII The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.

5. Variable Length Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>.<223> section that some may be missing.

6. PatentIn 2.0 "bug" A "bug" in PatentIn version 2.0 has caused the <220>.<223> section to be missing from amino acid sequence(s). Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>.<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>.<223> sections for Artificial or Unknown sequences.

7. Skipped Sequences (OLD RULES) Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence:
(2) INFORMATION FOR SEQ ID NO X (insert SEQ ID NO where "X" is shown)
(1) SEQUENCE CHARACTERISTICS (Do not insert any subheadings under this heading)
(4) SEQUENCE DESCRIPTION SEQ ID NO X (insert SEQ ID NO where "X" is shown)
This sequence is intentionally skipped

Please also adjust the "(1) NUMBER OF SEQUENCES" response to include the skipped sequences.

8. Skipped Sequences (NEW RULES) Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence:
<210> sequence id number
<400> sequence id number
000

9. Use of n's or Xaa's (NEW RULES) Use of n's and/or Xaa's have been detected in the Sequence Listing.
Per 1.823 of Sequence Rules, use of <220>.<223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.

10. Invalid <213> Response Per 1.823 of Sequence Rules, the only valid <213> responses are Unknown, Artificial Sequence, or scientific name (Genus/species). <220>.<223> section is required when <213> response is Unknown, Artificial Sequence.

11. Use of <220>

Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown". Please explain source of genetic material in <220> to <223> section (See "Federal Register," 09/01/1998, Vol 63, No 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)

12. PatentIn 2.0 "bug"

Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.

13. Misuse of n/Xaa "n" can only represent a single nucleotide; "Xaa" can only represent a single amino acid

AMC - Biotechnology Systems Branch - 09/09/2003

Best Available Copy



PCT

RAW SEQUENCE LISTING

DATE: 03/24/2005

PATENT APPLICATION: US/10/527,662

TIME: 11:10:21

Input Set : A:\sequence listing.txt

Output Set: N:\CRF4\03242005\J527662.raw

5 <110> APPLICANT: Vlaams Interuniversitair Instituut voor Biotechnologie vzw
 9 <120> TITLE OF INVENTION: A method for the identification of drug targets
 13 <130> FILE REFERENCE: JVK-ChP-V127
 C--> 17 <140> CURRENT APPLICATION NUMBER: US/10/527,662
 C--> 17 <141> CURRENT FILING DATE: 2005-03-11
 17 <150> PRIOR APPLICATION NUMBER: EP 02078801.4
 19 <151> PRIOR FILING DATE: 2002-09-12
 23 <160> NUMBER OF SEQ ID NOS: 8
 27 <170> SOFTWARE: PatentIn version 3.1
 31 <210> SEQ ID NO: 1
 33 <211> LENGTH: 5
 35 <212> TYPE: PRT
 37 <213> ORGANISM: Artificial Sequence
 41 <220> FEATURE:
 43 <223> OTHER INFORMATION: Peptide used in figure 3B and is acetylated.
 45 <400> SEQUENCE: 1
 47 Phe Ile Glu Gly Arg
 48 1 5
 51 <210> SEQ ID NO: 2
 53 <211> LENGTH: 11
 55 <212> TYPE: PRT
 57 <213> ORGANISM: Artificial Sequence
 61 <220> FEATURE:
 63 <223> OTHER INFORMATION: The peptide used in example 1.2: has an acetylated free
 alpha-NH2
 64 terminus and a free COOH-terminus.
 66 <400> SEQUENCE: 2
 68 Phe Ile Glu Gly Arg Ala Asp Ser Lys Ser Ser
 69 1 5 10
 72 <210> SEQ ID NO: 3
 74 <211> LENGTH: 10
 76 <212> TYPE: PRT
 78 <213> ORGANISM: Artificial Sequence
 82 <220> FEATURE:
 84 <223> OTHER INFORMATION: The peptide in example 1.3; the Asp group carries an
 aldehyde, th
 85 e first Ala is acetylated.
 87 <400> SEQUENCE: 3
 89 Ala Ala Ile Glu Gly Arg Tyr Val Ala Asp
 90 1 5 10
 93 <210> SEQ ID NO: 4
 95 <211> LENGTH: 4
 97 <212> TYPE: PRT
 99 <213> ORGANISM: Artificial Sequence

What is the source of genetic material?
Does Not Comply Corrected Diskette Needed (pg. 1-3)
What is the source of genetic material?
Invalid response
What is the source of genetic material?
Invalid response
What is the source of genetic material?
Invalid response
See item # 11 on error summary sheet

103 <220> FEATURE:

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/527,662

DATE: 03/24/2005

TIME: 11:10:21

Input Set : A:\sequence listing.txt

Output Set: N:\CRF4\03242005\J527662.raw

105 <223> OTHER INFORMATION: The peptide in example 1.3; the Asp group carries an aldehyde, th

106 e Tyr is acetylated.

108 <400> SEQUENCE: 4

110 Tyr Val Ala Asp

111 1

114 <210> SEQ ID NO: 5

116 <211> LENGTH: 6

118 <212> TYPE: PRT

120 <213> ORGANISM: Artificial Sequence

124 <220> FEATURE:

126 <223> OTHER INFORMATION: The peptide used in example 1.5 and Lys carries 19-actin-50.

128 <400> SEQUENCE: 5

130 Ala Asp Ser Lys Ser Ser

131 1 5

134 <210> SEQ ID NO: 6

136 <211> LENGTH: 5

138 <212> TYPE: PRT

140 <213> ORGANISM: Artificial Sequence

144 <220> FEATURE:

146 <223> OTHER INFORMATION: Peptide used in example 1.5; sequence from the compound peptide.

148 <220> FEATURE:

150 <221> NAME/KEY: MISC_FEATURE

152 <222> LOCATION: (4)..(4)

154 <223> OTHER INFORMATION: XAA can be any amino acid.

158 <400> SEQUENCE: 6

W--> 160 Ala Asp Ser Xaa Ser

161 1 5

164 <210> SEQ ID NO: 7

166 <211> LENGTH: 9

168 <212> TYPE: PRT

170 <213> ORGANISM: Artificial Sequence

174 <220> FEATURE:

176 <223> OTHER INFORMATION: Peptide used in example 1.5; sequence derived from 19-27 actin se

177 quence.

179 <400> SEQUENCE: 7

181 Ala Gly Phe Ala Gly Asp Asp Ala Pro

182 1 5

185 <210> SEQ ID NO: 8

187 <211> LENGTH: 5

189 <212> TYPE: PRT

191 <213> ORGANISM: Artificial Sequence

195 <220> FEATURE:

197 <223> OTHER INFORMATION: The peptide is used in example 1.6: the NH2-terminal part of the

198 compound peptide; the Phe is acetylated.

200 <400> SEQUENCE: 8

202 Phe Ile Glu Glu Arg

203 1 5

Invalid response

See item #11 on error summary sheet

Same error

Same error

Same error

Same error

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/10/527,662

DATE: 03/24/2005
TIME: 11:10:22

Input Set : A:\sequence listing.txt
Output Set: N:\CRF4\03242005\J527662.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:6; Xaa Pos. 4 ✓

VERIFICATION SUMMARY

PATENT APPLICATION: US/10/527,662

DATE: 03/24/2005

TIME: 11:10:22

Input Set : A:\sequence listing.txt

Output Set: N:\CRF4\03242005\J527662.raw

L:17 M:270 C: Current Application Number differs, Replaced Current Application No

L:17 M:271 C: Current Filing Date differs, Replaced Current Filing Date

L:160 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:0

